2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | INTEGRATIVE CANCER THERAPIES INTEGR CANCER THER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 5.9
50人评分
我要评分
声誉 7.0 影响力 4.9 速度 7.0 | |||||||||||||||||||||
期刊ISSN | 1534-7354 | 微信扫码收藏此期刊 | ||||||||||||||||||||
E-ISSN | 1552-695X | |||||||||||||||||||||
2022-2023最新影响因子 (数据来源于搜索引擎) | 2.9 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2024年3月26日:2.589 | |||||||||||||||||||||
2022-2023自引率 | 3.40%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 3.7 | |||||||||||||||||||||
h-index | 53 | |||||||||||||||||||||
CiteScore |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | https://us.sagepub.com/en-us/nam/integrative-cancer-therapies/journal201510 | |||||||||||||||||||||
期刊投稿网址 | https://us.sagepub.com/en-us/nam/integrative-cancer-therapies/journal201510#submission-guidelines | |||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足INTEGRATIVE CANCER THERAPIES的语言要求,还能让INTEGRATIVE CANCER THERAPIES编辑和审稿人得到更好的审稿体验,让稿件最大限度地被INTEGRATIVE CANCER THERAPIES编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费:需要( USD2650; ) 文章处理费豁免:查看说明 其他费用:没有 期刊主题关键词:health psychology、oncology、integrative care、cancer、alternative medicine、complementary medicine 相关链接:Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
通讯方式 | SAGE PUBLICATIONS INC, 2455 TELLER RD, THOUSAND OAKS, USA, CA, 91320 | |||||||||||||||||||||
出版商 | SAGE Publications Inc. | |||||||||||||||||||||
涉及的研究方向 | 医学-全科医学与补充医学 | |||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | Quarterly | |||||||||||||||||||||
出版年份 | 2002 | |||||||||||||||||||||
年文章数 | 90点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 92.41% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 72.22% | |||||||||||||||||||||
WOS期刊SCI分区 ( 2022-2023年最新版) | WOS分区等级:2区
| |||||||||||||||||||||
中科院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中科院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
中科院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||
中科院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1534-7354%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: >12周,或约稿 | |||||||||||||||||||||
平均录用比例 | 网友分享经验: 较易 | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在INTEGRATIVE CANCER THERAPIES顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
中国学者近期发表的论文 | |
1. | Aidi Injection, a Traditional Chinese Medicine Injection, Could Be Used as an Adjuvant Drug to Improve Quality of Life of Cancer Patients Receiving Chemotherapy: A Propensity Score Matching Analysis. Author: Xie G1, Cui Z1, Peng K1, Zhou X1, Xia Q2,3, Xu D1,2,3. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735418810799. doi: 10.1177/1534735418810799. Epub 2018 Nov 27. PubMed DOI |
2. | Shenqi Fuzheng Injection in the Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials. Author: Liu S1, Zhang D1, Wu J1, Wang K1, Zhao Y1, Ni M1, Meng Z1, Zhang X1. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735418816824. doi: 10.1177/1534735418816824. Epub 2018 Dec 4. PubMed DOI |
3. | Integrative Herbal Medicine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer: A Systematic Review and Meta-Analysis. Author: Liu Y1, May BH2, Zhang AL2, Guo X1, Lu C1, Xue CC1,2, Zhang H1. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735418817833. doi: 10.1177/1534735418817833. Epub 2018 Dec 10. PubMed DOI |
4. | A Purified Resin Glycoside Fraction from Pharbitidis Semen Induces Paraptosis by Activating Chloride Intracellular Channel-1 in Human Colon Cancer Cells. Author: Zhu D1, Chen C1, Xia Y1, Kong LY1, Luo J1. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735418822120. doi: 10.1177/1534735418822120. Epub 2019 Jan 7. PubMed DOI |
5. | Effects of Shen Cao Granules on Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancer Patients: A Randomized Controlled Trial. Author: Yu C1, Liu W1, Mu Y1, Hou A1, Li Y1. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735419829568. doi: 10.1177/1534735419829568. PubMed DOI |
6. | Combination of Astragali Polysaccharide and Curcumin Improves the Morphological Structure of Tumor Vessels and Induces Tumor Vascular Normalization to Inhibit the Growth of Hepatocellular Carcinoma. Author: Tang D1, Zhang S2, Shi X1, Wu J1, Yin G1, Tan X3, Liu F1, Wu X1, Du X1. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735418824408. doi: 10.1177/1534735418824408. PubMed DOI |
7. | Meta-Analysis of 5-Fluorouracil-Based Chemotherapy Combined With Traditional Chinese Medicines for Colorectal Cancer Treatment. Author: Chen P1,2, Ni W2, Xie T1,2, Sui X2. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735419828824. doi: 10.1177/1534735419828824. PubMed DOI |
8. | Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China. Author: Zhang D1, Wu J1, Duan X1, Wang K1, Ni M1, Liu S1, Zhang X1, Zhang B1, Zhao Y1. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735419827098. doi: 10.1177/1534735419827098. PubMed DOI |
9. | The Efficacy of Cognitive Behavioral Therapy to Treat Depression and Anxiety and Improve Quality of Life Among Early-Stage Breast Cancer Patients. Author: Sun H1, Huang H2, Ji S1, Chen X1, Xu Y2, Zhu F3, Wu J1. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735419829573. doi: 10.1177/1534735419829573. PubMed DOI |
10. | Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study. Author: Li CL1, Hsia TC2,3,4,5, Li CH2,3,4, Chen KJ5, Yang YH5,6,7, Yang ST8,9. Journal: Integr Cancer Ther. 2019 Jan-Dec;18:1534735419827079. doi: 10.1177/1534735419827079. PubMed DOI |
|
|
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分: | |
同领域作者分享投稿经验:共67条 (包含回复) |
我来分享 |
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海分公司 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960
增值电信业务经营许可证:沪B2-20211595
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451